Press Releases

Press Releases

May 7, 2019
WAYLIVRA is the only therapy for Familial Chylomicronemia Syndrome, or FCS, a devastating, ultra-rare disease BOSTON and CARLSBAD, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc.
May 2, 2019
Multiple clinical presentations at AAN focus on the long-term clinical benefits of treatment with TEGSEDI™   (inotersen) An oral presentation of long-term efficacy and safety with 2-year data from the NEURO-TTR open-label study to be presented by Dr. Tom Brannagan BOSTON , May 02, 2019 (GLOBE
April 24, 2019
Webcast scheduled for Wednesday, May 8th at 4:30 p.m. Eastern Time BOSTON , April 24, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , announced today that it will host a live webcast on Wednesday, May 8 th at 4:30 p.m.
March 15, 2019
Presentations focus on the benefits of treatment with TEGSEDI™ (inotersen) and results show continued efficacy with long-term exposure in the NEURO-TTR open-label extension study BOSTON and CARLSBAD, Calif., March 15, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc.
March 1, 2019
First and only therapy approved for FCS, a serious and rare disease with no approved treatment options BOSTON, Mass. and CARLSBAD, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals,
February 28, 2019
Planned activities to highlight wide-ranging impact of rare diseases on patients and challenges in disease management, including important perspectives from caregivers BOSTON , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc.
February 26, 2019
TEGSEDI™ (inotersen) commercially available in United States , European Union & Canada Achieved Fourth Quarter 2018 TEGSEDI® (inotersen) Global Net Product Revenues of $2.2 Million Conference Call Webcast Tuesday, February 26 , 4:30 p.m. ET at www.akceatx.com   BOSTON , Feb.
February 25, 2019
Phase 3 planning and initiation activities underway Akcea earns $150M license fee BOSTON and CARLSBAD, Calif., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that
February 20, 2019
BOSTON , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced that management will present a company overview at the
February 13, 2019
Webcast scheduled for Tuesday, February 26th at 4:30 p.m. Eastern Time BOSTON , Feb. 13, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , announced today that it will host a live webcast on Tuesday, February 26 th at 4:30 p.m.